The purpose of the TII study is to see how the prebiotic inulin changes the gut bacteria (microbiome) of children and young adults (ages 8-21) with IBD and determine if this dietary intervention can help reduce disease activity.

The purpose of this research study is to help us understand how well tofacitinib works as a treatment for ulcerative colitis or indeterminate colitis in pediatric patients.

The purpose of this study is to see if a new topical (applied to the skin) formulation of rapamycin, PTX-022, is safe and effective in treating participants with microcystic Lymphatic Malformations (mLM).

Transcend, Triumph, and Thrive (3T) is a HIV prevention intervention study for transgender youth ages 15-24, looking at their use of Pre-exposure prophylaxis (PrEP). The purpose of this study is to pilot a program designed to address the health needs of transgender youth.

This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine 15 days per month or more.

This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine less than 15 days per month.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").

The purpose of this research study is to identify genes that are involved in the development of Inflammatory Bowel Disease (IBD) at a young age (less than 8 years of age).

The purpose of this study is to see if a new investigational drug (Upadacitinib) is safe and well tolerated and also to determine the appropriate dose for subjects with polyarticular course juvenile arthritis (pcJIA).

Our team at the Congenital Hyperinsulinism Center at CHOP is working on a clinical drug trial that involves giving you a study drug called UX033.